On January 8, 2019 Systems Oncology, an AI-based biopharmaceutical company, reported that Dr. Spyro Mousses, Chief Executive Officer, will present their rapidly growing pipeline of innovative oncology programs discovered with their ExpansiveAI platform, during the 37th annual J.P. Morgan Healthcare Conference in San Francisco, CA (Press release, Systems Oncology, JAN 8, 2019, View Source [SID1234532586]). The presentation is scheduled for Wednesday, January 9th at 10:45AM PST as part of Pitch Day presented by eChinaHealth.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will give specific examples of new programs and collaborative research opportunities that emerged from Systems Oncology’s unique ability to translate big data into novel insights. Systems Oncology then leverages its unique insights into cancer biology and clinical/regulatory development opportunities to enter into in-licensing and out-licensing deals with organizations around the world to build drug development programs and collaborate with partners to drive these programs forward. Systems Oncology recently closed another two deals: its first deal in China, an in-licensing agreement with a major Chinese university; and its first venture into Japan, an out-licensing collaboration with Toray Industries, a large Japanese corporation, on TRK-880, a novel anti-cancer drug that is projected to be effective across many cancer indications. The presentation at the eChinaHealth event will highlight some of these successful international programs and express Systems Oncology’s interest to continue to collaborate and partner with organizations in Asia as part of its overall global outreach.

On January 8, 2019 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported the sale of its residual rights to receive royalty payments on commercial sales of Kadcyla (ado-trastuzumab emtansine) to OMERS, the defined benefit pension plan for municipal employees in the Province of Ontario, Canada, for $65 million (Press release, ImmunoGen, JAN 8, 2019, View Source [SID1234532585]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"ImmunoGen played a key role in the generation and early development of Kadcyla, the first ADC approved for the treatment of HER2-positive breast cancer, and we are pleased to see the continued progress of this important therapy in the market," said Mark Enyedy, President and Chief Executive Officer. "As ImmunoGen evolves into a fully-integrated company with our proprietary portfolio, this transaction further strengthens our balance sheet as we execute on our strategic priorities and work to deliver more good days to people living with cancer."

This transaction entails the sale of the residual interest held by ImmunoGen from a prior transaction with Immunity Royalty Holdings, L.P. (IRH). In 2015, ImmunoGen announced a $200 million non-dilutive royalty transaction through which ImmunoGen sold the right to receive 100% of the royalty revenue on Kadcyla commercial sales to an undisclosed threshold amount, subject to certain conditions. Once the applicable threshold was met, ImmunoGen would receive 85% of the Kadcyla royalty revenue and the original purchaser would receive 15% for the remaining term of the royalty. With this transaction, OMERS now owns 100% of ImmunoGen’s rights to receive Kadcyla royalties.

MTS Health Partners, L.P. acted as exclusive financial advisor to ImmunoGen and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. acted as special transactional counsel to ImmunoGen.

ABOUT KADCYLA ROYALTIES

Genentech, a member of the Roche Group, developed Kadcyla (ado-trastuzumab emtansine) using ADC technology licensed from ImmunoGen under a 2000 agreement established between the companies. This agreement entitles ImmunoGen to receive royalties ranging from 3-5% on Kadcyla sales in countries where ImmunoGen holds valid patents covering Kadcyla, and 2% in countries without relevant ImmunoGen patents. ImmunoGen is entitled to receive royalties on commercial Kadcyla sales in each country for ten years after the launch of Kadcyla in that country. This period extends to twelve years for each country in which ImmunoGen has valid claims in relevant patents on the tenth anniversary of the commercial launch of Kadcyla in that country.

ABOUT OMERS

Founded in 1962, OMERS is one of Canada’s largest defined benefit pension plans, with more than $95 billion in net assets, as at December 31, 2017. It invests and administers pensions for almost half a million members from municipalities, school boards, emergency services, and local agencies across Ontario. OMERS has employees in Toronto and other major cities across North America, the U.K., Europe, Asia, and Australia – originating and managing a diversified portfolio of investments in public markets, private equity, infrastructure, and real estate. For more information, please visit www.omers.com.

On January 8, 2019 Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, reported that in 2018 it entered into agreements with 10 new companies (Press release, Adimab, JAN 8, 2019, View Source [SID1234532584]). In addition, Adimab announced the expansion of seven of its current partnerships and the achievement of 70 technical and development milestones across numerous collaborations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the past ten years, Adimab has partnered with over 60 companies for the discovery of therapeutic IgGs and bispecific antibodies, resulting in more than 260 therapeutic programs derived from the Adimab Platform. In 2018, Adimab and its partners added 56 new therapeutic programs. New alliances for 2018 include collaborations with Biotheus, Boehringer Ingelheim, Cullinan Oncology, Cygnal Therapeutics, Pliant Therapeutics, REGiMMUNE, and Werewolf Therapeutics, among others. In addition, Adimab expanded its collaborations with Boehringer Ingelheim, Innovent Biologics, Mapp Biopharmaceutical, Sanofi, Surface Oncology, and Takeda.

"In 2018, we saw fantastic growth in the number of therapeutic programs coming from our platform," said Guy Van Meter, Senior Vice President of Business Development. "In addition to being the leader for antibody discovery, Adimab has become the go-to provider for bispecifics and protein engineering. Our partners really benefit from our deep domain expertise and get to access all our capabilities."

"In an industry that is used to exaggerated claims, we have proven time and time again that we deliver the highest quality therapeutic leads," added Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "To date more than 80% of our partners have expanded their partnership with Adimab, which is a meaningful indicator of the quality of our work."

Over the past five years, Adimab has worked with an increasing number of smaller companies, backed by leading venture capital firms. Following successful antibody discovery campaigns, many of these companies have gone on to partner their programs with larger pharmaceutical companies. Publicly announced transactions include: Tizona and Abbvie (2019), Dragonfly and Merck (2018), Tusk and Roche (2018), Scholar Rock and Gilead (2018), Alector and Abbvie (2017), Dragonfly and Celgene (2017), Mersana and Takeda (2016), Surface Oncology and Novartis (2016), Potenza and Astellas (2015, 2018), and Innovent and Lilly (2015).

"Roche was very thorough in their diligence, and the quality of the leads and the data from Adimab made the process much smoother," said Luc Dochez, former Chief Executive Officer of Tusk Therapeutics.

"Investors and partners invariably conduct extensive diligence on the structural and pharmacological properties of our drug leads," said Arnon Rosenthal, Co-Founder and Chief Executive Officer of Alector. "Adimab data and the support of the Adimab team were critical elements in developing compelling product candidates."

"Adimab has been a fantastic partner. The Adimab team is comprised of leading scientists, using state of the art technology, who have a sense of urgency towards their collaborators. I cannot praise them highly enough," said Bill Haney, Co-Founder and Chief Executive Officer of Dragonfly Therapeutics.

On January 8, 2019 UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, reported topline results from the ongoing pivotal Phase 3 OLYMPUS clinical trial of UGN-101 (mitomycin gel) for instillation, an investigational mitomycin formulation for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC) (Press release, UroGen Pharma, JAN 8, 2019, View Source [SID1234532583]). This analysis showed that on an intent-to-treat basis, 57 percent of patients achieved a complete response (CR) rate at their primary disease evaluation (PDE, or the primary endpoint) which was conducted four to six weeks after completion of UGN-101 treatment. Importantly, all evaluated patients in CR remain disease free at six months.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This international, multi-center trial completed enrollment with 71 patients in December 2018. Of the 71 patients enrolled in the trial, 61 patients have been evaluated for the primary endpoint which was a CR as defined as a negative ureteroscopic evaluation and a negative wash cytology. The remaining 10 patients are awaiting PDE evaluation.

"We are pleased to report that the CR and durability data remain consistent with the Interim Analysis presented in May 2018. These results continue to validate the potential of UGN-101 to shift the surgical treatment paradigm and benefit patients whose only alternative would be repetitive endoscopic surgical intervention or complete loss of a kidney," said Mark P. Schoenberg, M.D., Chief Medical Officer of UroGen. "The durability observed in the OLYMPUS study provides further evidence that the non-surgical treatment of LG UTUC with UGN-101 may result in clinically-meaningful, recurrence free survival. We are grateful to the patients, their families, and clinical investigators who have made this important study possible."

Approximately 45 percent of tumors treated were categorized as unresectable by surgery at baseline. Of the patients who achieved CR, UroGen now has six-month durability on half of these patients. Durability is a key secondary endpoint for the trial.

The safety profile of UGN-101 continues to be acceptable with most treatment-emergent adverse events characterized as mild or moderate and transient and in line with ureteral procedures. These included ureteral narrowing and hydronephrosis, urinary tract infection, flank pain and creatinine elevation.

UroGen intends to seek regulatory approval of UGN-101 in LG UTUC based on data from all 71 patients and initiated its rolling submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in December 2018. The FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to UGN-101 for the treatment of UTUC. If approved, UGN-101 would be the first drug approved for the non-surgical treatment of LG UTUC.

Seth Paul Lerner, M.D., FACS, Professor of Urology at Baylor College of Medicine in Houston, Texas served as Principal Investigator of the OLYMPUS trial.

About UGN-101

UGN-101 (mitomycin gel) for instillation is an investigational drug formulation of mitomycin in Phase 3 development for the treatment of low-grade upper tract urothelial cancer (LG UTUC). Utilizing the RTGel technology platform, UroGen’s proprietary sustained release, hydrogel-based formulation, UGN-101 is designed to enable longer exposure of mitomycin to urinary tract tissue, thereby enabling the treatment of tumors by non-surgical means. UGN-101 is delivered to patients using standard ureteral catheters.

On January 8, 2019 Biond Biologics Ltd. ("Biond" or the "Company"), a privately-held Israeli biotechnology company, developing novel immunotherapies for cancer and autoimmune diseases, reported the closing of a $17 million Series B financing (Press release, Biond Biologics, JAN 8, 2019, View Source [SID1234532582]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Biond was founded in 2016 by the former scientific team of cCam Biotherapeutics, an immuno-oncology company which was fully acquired by Merck in July 2015. The former cCAM Biotherapeutics team was joined by additional veterans of the Israeli biotech industry, with the aim to build a strong, sustainable and innovative science-driven biotechnology company. The company’s vision and strategy are to bring innovative drugs to patients based on synergistic long-term collaborations with leading global companies in the immunotherapy field.

Biond intends to use the proceeds to move its lead drug candidate, BION-202, into clinical trials and to advance the preclinical development of BION-206 and its proprietary antibody cell-internalization technology.

The financing and due diligence were led by Israel Biotech Fund and Harel Insurance & Finance Group, with participation of Celgene Corporation, (NASDAQ: CELG), the Japanese-Israeli fund, SBI JI Innovation Fund and existing investors.

"We are excited to have such prominent investors as shareholders who are aligned with the company’s vision of delivering breakthrough immune-based solutions to patients with serious diseases," said Dr. Tehila Ben Moshe, Co-Founder and Chief Executive Officer of Biond Biologics. "After two years of intense and creative discovery work, we are ready to advance our first innovative drug candidate into clinical trials."

"We were very impressed by the innovative science discovered at Biond and by the quality and experience of its managerial and scientific team," said Dr. David Sidransky, M.D., Co-Founder and General Partner at Israel Biotech Fund and Biond board member. "Biond’s novel pipeline candidates have the potential of becoming paradigm shifting therapies in immuno-oncology."

"We are happy to support the outstanding management team at Biond and its cutting-edge pipeline and technology," stated at Harel Insurance & Finance. "This investment aligns with the group’s ongoing effort of investing in breakthrough and innovative technologies developed by companies with great growth potential."